• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

5.990 +0.290 (+5.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,871
Open 5.590
Bid (Size) 5.550 (300)
Ask (Size) 5.990 (100)
Prev. Close 5.700
Today's Range 5.460 - 6.050
52wk Range 3.350 - 17.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 09, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
June 02, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-54.6%
-54.6%
1 Month
+66.9%
+66.9%
3 Month
+45.0%
+45.0%
6 Month
-54.9%
-54.9%
1 Year
-57.0%
-57.0%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
May 26, 2026
From Pomerantz LLP
Via GlobeNewswire
Here are the top movers in Friday's session. ↗
May 15, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
May 15, 2026
Via Chartmill
These stocks are moving in today's pre-market session ↗
May 15, 2026
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
May 14, 2026
Via Chartmill
News headline image
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 14, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 07, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 24, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 17, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 10, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
March 04, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
March 03, 2026
From Pomerantz LLP
Via GlobeNewswire
Monday's session: top gainers and losers ↗
March 02, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
March 02, 2026
Via Chartmill
News headline image
AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗
March 02, 2026
Via Stocktwits
Get insights into the top gainers and losers of Monday's pre-market session. ↗
March 02, 2026
Via Chartmill
News headline image
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
February 28, 2026
From The Schall Law Firm
Via Business Wire
News headline image
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗
February 27, 2026
Via Stocktwits
Top movers in Friday's after hours session ↗
February 27, 2026
Via Chartmill
News headline image
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
February 27, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
News headline image
Aardvark Therapeutics Announces Leadership Appointments
February 12, 2026
From Aardvark Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 5.990
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 07/06/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap